( NASDAQ-SMALL:NWBO, OTC-PINK:NWBO, OTC-QB:NWBO )

News from Northwest Biotherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 04, 2017, 13:39 ET NW Bio Announces Completion of $12 Million Financing

Northwest Biotherapeutics (OTCQB: NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Oct 17, 2017, 11:44 ET NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Sep 20, 2017, 08:00 ET NW BIO Announces Registered Direct Offering Of $1.75 Million

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Sep 01, 2017, 14:49 ET DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Jun 05, 2017, 09:17 ET Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Mar 23, 2017, 12:49 ET NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Mar 17, 2017, 09:00 ET NW BIO Announces Registered Direct Offering Of $7.5 Million

Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Mar 10, 2017, 08:15 ET NW Bio Reaches Agreement With Convertible Note Holders

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...


Feb 06, 2017, 09:30 ET NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Jan 18, 2017, 15:28 ET NW Bio Presenting At Phacilitate Immunotherapy World Conference

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...


Dec 20, 2016, 09:29 ET NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Dec 19, 2016, 09:39 ET NW Bio Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016

Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Dec 08, 2016, 14:04 ET NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Dec 07, 2016, 20:00 ET NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Nov 17, 2016, 08:15 ET NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Oct 21, 2016, 09:45 ET NW BIO Announces Registered Direct Offering

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Sep 29, 2016, 09:26 ET NW Bio Presents Further DCVax®-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid...


Sep 06, 2016, 08:55 ET NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune...


Jul 05, 2016, 09:00 ET NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $3.7 MILLION WITH NEW INSTITUTIONAL INVESTORS

 Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...


Jun 13, 2016, 09:15 ET NW Bio Announces Scientific Advisory Board

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid...


Jan 25, 2016, 09:30 ET NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise

 Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...


Dec 24, 2015, 16:29 ET NW Bio Announces Closing Of Registered Direct Offering of $12.6 Million

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Dec 23, 2015, 09:00 ET NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $12.6 MILLION

 Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...


Dec 21, 2015, 13:05 ET NW Bio Announces Annual Meeting Results, Re-Election of Directors

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...


Dec 08, 2015, 08:15 ET NW Bio Announces Establishment of Special Committee And Law Firm To Conduct Independent Investigation of Recent Allegations

 Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...